Song et al. first reported the use of nimotuzumab, a humanized anti-EGFR monoclonal antibody (mAb) that blocks cancer cell proliferation, invasion, and metastasis, to treat an 87-year-old HCC patient, resulting in complete disease remission. This evidence concerns the gene EGFR and hepatocellular carcinoma.